SCHEMBL2660889

SCHEMBL2660889

Nc1n[nH]c2cccc(C(F)(F)F)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.56
▸ PDPK1 O15530 2/20 0.56
▸ MAP2K1 Q02750 2/20 0.51
▸ KDR P35968 8/20 0.51
▸ ABL1 P00519 7/20 0.51
▸ LCK P06239 2/20 0.51
▸ CSF1R P07333 2/20 0.51
▸ FGFR1 P11362 2/20 0.51
▸ PRKACA P17612 2/20 0.51
▸ ROCK1 Q13464 2/20 0.51
▸ DAPK3 O43293 1/20 0.51
▸ PRKD3 O94806 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ PAK4 O96013 1/20 0.51
▸ NTRK1 P04629 1/20 0.51
▸ RET P07949 1/20 0.51
▸ IGF1R P08069 1/20 0.51
▸ MET P08581 1/20 0.51
▸ PDGFRB P09619 1/20 0.51
▸ FLT1 P17948 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592736 0.85 KDR (0.56) GAAPDPK1MAP2K1KDRABL1
SCHEMBL16681253 0.85 KDR (0.56) GAAPDPK1MAP2K1KDRABL1
SCHEMBL13236555 0.82 PDPK1 (0.56) GAAPDPK1MAP2K1KDRABL1
SCHEMBL24852599 0.81 KDR (0.48) GAAPDPK1MAP2K1KDRABL1
SCHEMBL30168107 0.81 KDR (0.48) GAAPDPK1MAP2K1KDRABL1
SCHEMBL30788040 0.79 PDPK1 (0.53) GAAPDPK1MAP2K1KDRABL1
SCHEMBL24853341 0.79 PDPK1 (0.53) GAAPDPK1MAP2K1KDRABL1
SCHEMBL14631560 0.79 AXL (0.46) GAAPDPK1MAP2K1KDRABL1
SCHEMBL25475400 0.79 AXL (0.46) GAAPDPK1MAP2K1KDRABL1
SCHEMBL13122322 0.79 AXL (0.46) GAAPDPK1MAP2K1KDRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-06-02 — — US disclosed
EP-3066100-B1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS Bayer Pharma AG (DE) 2019-04-17 — — EP disclosed
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-06 — — US disclosed
US-10098883-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-10-16 — — US disclosed
CN-105683194-B The inhibitor of (azepine) pyrido PyrazolopyrimidinonecGMP and indazole hepyramine as fibrinolysis 拜耳制药股份公司 2018-09-14 — — CN disclosed
US-20170239251-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-24 — — US disclosed
US-9598417-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-21 — — US disclosed
EP-3066100-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS Bayer Pharma Aktiengesellschaft (DE) 2016-09-14 — — EP disclosed
CN-105683194-A (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis 拜耳制药股份公司 2016-06-15 — — CN disclosed
WO-2015067549-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-14 — — WO disclosed
US-20150126449-A1 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-07 — — US disclosed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 — — EP disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 — — WO disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 — — WO disclosed
US-4051252-A ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC BAYER AKTIENGESELLSCHAFT (DT) 1977-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180344739-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885
US-20070244169-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GAA 54/4885PDPK1 148/4885MAP2K1 1211/4885
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885
US-20150126449-A1 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885
US-20170239251-A1 (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885
US-10098883-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 GAA 3619/4885PDPK1 1304/4885MAP2K1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback